Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
äŒæ¥ã³ãŒãNNNN
äŒç€ŸåAnbio Biotechnology
äžå Žæ¥Feb 19, 2025
æé«çµå¶è²¬ä»»è
ãCEOãLau (Michael)
åŸæ¥å¡æ°27
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 19
æ¬ç€Ÿæåšå°Friedrich-Ebert-Anlage 49
éœåžFRANKFURT AM MAIN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœGermany
éµäŸ¿çªå·60308
é»è©±çªå·4916096247281
ãŠã§ããµã€ãhttps://anbiobiotechnology.com/
äŒæ¥ã³ãŒãNNNN
äžå Žæ¥Feb 19, 2025
æé«çµå¶è²¬ä»»è
ãCEOãLau (Michael)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã